Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359138 | 0.77 | GAA (0.52) | GAAALDH1A1TSHRCYP2D6CYP2C9 | |
| SCHEMBL28161161 | 0.74 | GAA (0.44) | GAAALDH1A1TSHRCYP2D6CYP2C9 | |
| SCHEMBL4464867 | 0.74 | GAA (0.44) | GAAALDH1A1TSHRCYP2D6CYP2C9 | |
| SCHEMBL18253 | 0.72 | GAA (0.42) | GAAALDH1A1TSHR | |
| SCHEMBL5201001 | 0.72 | GAA (0.42) | GAAALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL338771 | 0.72 | GAA (0.42) | GAAALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL2717509 | 0.72 | GAA (0.42) | GAAALDH1A1TSHR | |
| SCHEMBL6315329 | 0.72 | GAA (0.42) | GAAALDH1A1TSHR | |
| Bromide SCHEMBL9125384 | 0.72 | GAA (0.42) | GAAALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL6312350 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431481-A | Cordycepin derivative and preparation method and application thereof | 燕山大学 | 2025-02-14 | — | — | CN | claimed |
| CN-119431466-A | Environment-friendly synthesis method of cordycepin by taking inosine as raw material | 深圳市倍昂生物科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-104961787-B | Synthetic method of cordycepin | 深圳松乐生物科技有限公司 | 2020-06-26 | — | — | CN | claimed |
| CN-110963915-A | Preparation process of 2-acetoxy isobutyryl bromide | 上海星酶生物科技有限公司 | 2020-04-07 | — | — | CN | claimed |
| US-7148322-B2 | Process for the preparation of echinocandin derivatives | NOVEXEL (FR) | 2006-12-12 | — | — | US | claimed |
| US-6927291-B2 | Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosides | PHARMASSET, LTD. (US) | 2005-08-09 | — | — | US | claimed |
| EP-1363927-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | Pharmasset Limited (US) | 2003-11-26 | — | — | EP | claimed |
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | GILEAD PHARMASSET LLC | 2002-12-26 | — | — | US | claimed |
| WO-2002070533-A2 | METHOD FOR THE SYNTHESIS OF 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | PHARMASSET LTD. (BB) | 2002-09-12 | — | — | WO | claimed |
| EP-0640091-A4 | SYNTHESIS OF NUCLEOTIDE MONOMERS. | RIBOZYME PHARM INC (US) | 1995-07-26 | — | — | EP | claimed |
| EP-0640091-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1993023413-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| US-5200514-A | SYNTHESIS OF 2'-DEOXYPYRIMIDINE NUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-04-06 | — | — | US | claimed |
| WO-1993006119-A1 | DEOXYNUCLEOSIDE DERIVATIVES | THE INSTITUTE OF CANCER RESEARCH (GB) | 1993-04-01 | — | — | WO | claimed |
| EP-0513067-A1 | A PRATICAL SYNTHESIS OF 2'-DEOXYNUCLEOSIDES AND 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-11-19 | — | — | EP | claimed |
| WO-1991010670-A1 | A PRATICAL SYNTHESIS OF 2'-DEOXYNUCLEOSIDES AND 2',3'-DIDEOXY-2',3'-DIDEHYDRONUCLEOSIDES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1991-07-25 | — | — | WO | claimed |
| EP-0341704-A2 | Process for the preparation of 2',3'-dideoxycytidines | F. HOFFMANN-LA ROCHE AG (CH) | 1989-11-15 | — | — | EP | claimed |
| JP-2256648-A | — | — | None | — | — | JP | disclosed |
| EP-0252683-A2 | Process and reagents for DNA sequence analysis | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-13 | — | — | EP | disclosed |
| EP-0251786-A2 | Alkynylamino-nucleotides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198224-A1 | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides | DUT, DUS2, DERA | GAA 627/4885ALDH1A1 853/4885TSHR 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.